Skip to main content
Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction
Quantitative Health Sciences Publications and Presentations
  • Harold L. Dauerman, University of Massachusetts Medical School
  • Darleen M. Lessard, University of Massachusetts Medical School
  • Jorge L. Yarzebski, University of Massachusetts Medical School
  • Mark I. Furman, University of Massachusetts Medical School
  • Joel M. Gore, University of Massachusetts Medical School
  • Robert J. Goldberg, University of Massachusetts Medical School
UMMS Affiliation
Department of Medicine, Division of Cardiovascular Medicine
Document Type
Medical Subject Headings
Aged; Angioplasty; Chemotherapy, Adjuvant; Electrocardiography; Female; Hospital Mortality; Humans; Incidence; Male; Massachusetts; Middle Aged; Myocardial Infarction; Regression Analysis; Thrombolytic Therapy; Treatment Outcome
The benefits of coronary reperfusion and antiplatelet therapy for patients with Q-wave acute myocardial infarction (Q-AMI) are well established in the context of randomized, controlled trials. The use and recent impact of these and other therapies on the broader, community-wide population of patients with Q-AMI is less well established. Residents of the Worcester, Massachusetts, metropolitan area (1990 census population 437,000) hospitalized with confirmed Q-AMI in all metropolitan Worcester, Massachusetts, hospitals in 4 1-year periods between 1986 and 1997 comprised the sample of interest. We examined the rates of occurrence, use of reperfusion strategies, and hospital mortality in a cohort of 711 patients with Q-AMI treated early in the reperfusion era (1986 and 1988) in comparison to 669 patients with Q-AMI treated a decade later (1995 and 1997). The percentage of Q-AMI among all hospitalized patients with AMI decreased over the decade of reperfusion therapy: 52% in 1986 and 1988 versus 35% in 1995 and 1997 (p < 0.001). Use of reperfusion therapy for patients with Q-AMI increased from 22% to 57%, with a marked increase in the use of primary angioplasty over time (1% vs 16%). The profile of patients receiving reperfusion therapy also changed significantly over the study period. Marked increases in use of antiplatelet therapy, beta blockers, angiotensin-converting enzyme inhibitors, and decreased use of calcium channel blockers, were observed over time. The crude in-hospital case fatality rate declined from 19% (1986 and 1988) to 14% (1995 and 1997) in patients with Q-AMI. Results of a multivariable regression analysis showed lack of reperfusion therapy, older age, anterior wall AMI, and cardiogenic shock to be independent predictors of in-hospital mortality in patients with Q-AMI. Thus, the percentage of all AMI's presenting as Q-AMI, and hospital mortality after Q-AMI, has decreased significantly in the past 10 years. The decrease in mortality occurs in the setting of broader use of reperfusion and adjunctive therapy (including primary angioplasty).
Rights and Permissions
Citation: Am J Cardiol. 2000 Oct 1;86(7):730-5.
Related Resources
Link to Article in PubMed
Citation Information
Harold L. Dauerman, Darleen M. Lessard, Jorge L. Yarzebski, Mark I. Furman, et al.. "Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction" Vol. 86 Iss. 7 (2000) ISSN: 0002-9149 (Linking)
Available at: